Core Insights - Milestone Scientific Inc. has appointed Dr. Dawood Sayed to its Board of Directors, enhancing the company's expertise in interventional pain management and supporting the commercial expansion of its CompuFlo® technology [1][4]. Company Overview - Milestone Scientific Inc. is a technology-focused medical research and development company that specializes in innovative injection technologies for medical and dental applications [6]. - The company's CompuFlo® Epidural System utilizes real-time pressure feedback to identify the epidural space, providing a safer alternative to traditional techniques [4]. Appointment of Dr. Sayed - Dr. Sayed is a recognized leader in interventional pain medicine, serving as a Professor and Division Chief at the University of Kansas Medical Center, and brings over a decade of experience in minimally invasive pain therapies [2]. - His role as Vice Chairman and Co-Founder of the American Society of Pain and Neuroscience (ASPN) positions him to influence access to innovative pain relief technologies [3]. - The appointment is seen as a strategic move to align the company with the needs of patients, physicians, and payers, facilitating the adoption of CompuFlo® in pain management and spine intervention markets [4][5]. Strategic Goals - The company aims to leverage Dr. Sayed's expertise in health system adoption and reimbursement strategies to accelerate growth in the interventional pain management sector [5]. - Dr. Sayed's involvement is expected to enhance clinical adoption of CompuFlo®, which addresses challenges in spinal procedures and aims to reduce reliance on opioids [5]. Market Position - The CompuFlo® technology has received validation from clinical leaders and has been assigned a Medicare Part B payment rate under CPT® code 0777T, indicating growing support from commercial insurers [4]. - The company is focused on advancing its proprietary DPS Dynamic Pressure Sensing Technology to improve patient comfort and safety during injections [6].
Milestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management